In vitro combination studies of tenofovir and other nucleoside analogues with ribavirin against HIV-1MARGOT, Nicolas A; MILLER, Michael D.Antiviral therapy (London). 2005, Vol 10, Num 2, pp 343-348, issn 1359-6535, 6 p.Article

Phenotypic Susceptibility to Bevirimat in Isolates from HIV-1-Infected Patients without Prior Exposure to BevirimatMARGOT, Nicolas A; GIBBS, Craig S; MILLER, Michael D et al.Antimicrobial agents and chemotherapy. 2010, Vol 54, Num 6, pp 2345-2353, issn 0066-4804, 9 p.Article

ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptaseNAEGER, Lisa K; MARGOT, Nicolas A; MILLER, Michael D et al.Antimicrobial agents and chemotherapy. 2002, Vol 46, Num 7, pp 2179-2184, issn 0066-4804Article

Long-term follow-up of patients taking tenofovir DF with low-level HIV-1 viremia and the K65R substitution in HIV-1 RTCHAPPELL, Brandi J; MARGOT, Nicolas A; MILLER, Michael D et al.AIDS (London). 2007, Vol 21, Num 6, pp 761-763, issn 0269-9370, 3 p.Article

Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations : analysis of enzyme processivity, chain-terminator removal and viral replicationNAEGER, Lisa K; MARGOT, Nicolas A; MILLER, Michael D et al.Antiviral therapy (London). 2001, Vol 6, Num 2, pp 115-126, issn 1359-6535Conference Paper

Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: Genotypic, phenotypic, and rebound analysesMARGOT, Nicolas A; ISAACSON, Erica; MCGOWAN, Lan et al.Journal of acquired immune deficiency syndromes (1999). 2003, Vol 33, Num 1, pp 15-21, issn 1525-4135, 7 p.Article

In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4MARGOT, Nicolas A; HLUHANICH, Rebecca M; JONES, Gregg S et al.Antiviral research. 2012, Vol 93, Num 2, pp 288-296, issn 0166-3542, 9 p.Article

Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovirMARCHAND, Bruno; WHITE, Kirsten L; LY, John K et al.Antimicrobial agents and chemotherapy. 2007, Vol 51, Num 8, pp 2911-2919, issn 0066-4804, 9 p.Article

Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosineSVAROVSKAIA, Evguenia S; MARGOT, Nicolas A; BAE, Andrew S et al.Journal of acquired immune deficiency syndromes (1999). 2007, Vol 46, Num 2, pp 174-180, issn 1525-4135, 7 p.Article

The balance between NRTI discrimination and excision drives the susceptibility of HIV-1 RT mutants K65R, M184V and K65R+M184VLY, John K; MARGOT, Nicolas A; MACARTHUR, Holly L et al.Antiviral chemistry & chemotherapy. 2007, Vol 18, Num 6, pp 307-316, issn 0956-3202, 10 p.Article

The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutationsWHITE, Kirsten L; CHEN, James M; FENG, Joy Y et al.Antiviral therapy (London). 2006, Vol 11, Num 2, pp 155-163, issn 1359-6535, 9 p.Article

Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations Associated with First-Line Stavudine-Containing Antiretroviral Therapy: Programmatic Implications for Countries Phasing Out StavudineTANG, Michele W; RHEE, Soo-Yon; RUXRUNGTHAM, Kiat et al.The Journal of infectious diseases. 2013, Vol 207, issn 0022-1899, S70-S77, SUP2Article

Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapyGOODMAN, Derrick D; YUN ZHOU; MARGOT, Nicolas A et al.AIDS (London). 2011, Vol 25, Num 3, pp 325-333, issn 0269-9370, 9 p.Article

Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DFMARGOT, Nicolas A; ISAACSON, Erica; MCGOWAN, Ian et al.AIDS (London). 2002, Vol 16, Num 9, pp 1227-1235, issn 0269-9370Article

Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication FitnessABRAM, Michael E; HLUHANICH, Rebecca M; SVAROVSKAIA, Evguenia S et al.Antimicrobial agents and chemotherapy. 2013, Vol 57, Num 6, pp 2654-2663, issn 0066-4804, 10 p.Article

Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarateMCCOLL, Damian J; MARGOT, Nicolas A; WULFSOHN, Michael et al.Journal of acquired immune deficiency syndromes (1999). 2004, Vol 37, Num 3, pp 1340-1350, issn 1525-4135, 11 p.Article

Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy : Genotypic and phenotypic analyses of study GS-96-408MILLER, Michael D; MARGOT, Nicolas A; LAMY, Patrick D et al.Journal of acquired immune deficiency syndromes (1999). 2001, Vol 27, Num 5, pp 450-458, issn 1525-4135Article

The A62V and S68G Mutations in HIV-1 Reverse Transcriptase Partially Restore the Replication Defect Associated With the K65R MutationSVAROVSKAIA, Evguenia S; FENG, Joy Y; MILLER, Michael D et al.Journal of acquired immune deficiency syndromes (1999). 2008, Vol 48, Num 4, pp 428-436, issn 1525-4135, 9 p.Article

A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RTWHITE, Kirsten L; MARGOT, Nicolas A; LY, John K et al.AIDS (London). 2005, Vol 19, Num 16, pp 1751-1760, issn 0269-9370, 10 p.Article

Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacityWHITE, Kirsten L; MARGOT, Nicolas A; WRIN, Terri et al.Antimicrobial agents and chemotherapy. 2002, Vol 46, Num 11, pp 3437-3446, issn 0066-4804, 10 p.Article

Development of HIV-1 Drug Resistance Through 144 Weeks in Antiretroviral-Naïve Subjects on Emtricitabine, Tenofovir Disoproxil Fumarate, and Efavirenz Compared With Lamivudine/Zidovudine and Efavirenz in Study GS-01-934MARGOT, Nicolas A; ENEJOSA, Jeff; CHENG, Andrew K et al.Journal of acquired immune deficiency syndromes (1999). 2009, Vol 52, Num 2, pp 209-221, issn 1525-4135, 13 p.Article

Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutationsWHITE, Kirsten L; CHEN, James M; MARGOT, Nicolas A et al.Antimicrobial agents and chemotherapy. 2004, Vol 48, Num 3, pp 992-1003, issn 0066-4804, 12 p.Article